Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness ...

Researchers have identified a neural biomarker of compulsive food cravings, and showed that it is suppressed by the ...

The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the ...

New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

Here are some of the stocks on the move Monday, Nov. 17. Novo Nordisk (NVO) announced it will cut the prices for consumers ...

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...

Weight-loss drug developer Zealand Pharma said it halted work on an early-stage obesity treatment candidate to focus on more promising programs, including one for which it teamed up with Swiss giant ...